IGDM is a not-for-profit organization with a companion for-profit company focused on applying a successful platform technology to discover new medicines for both the global poor and the advanced economies of the world

• Duke University spin out
• proprietary proteome capture discovery technology combines focused chemical libraries with parallel affinity capture screens rapidly identifying lead compound/target associations
• focused on infectious and parasitic diseases of the global poor and diseases such as cancer, obesity and respiratory ailments which afflict patients in the Southern and Western hemispheres
• commercially valuable assets for Western diseases discovered during the screening process are exchanged for royalties & equity to create self-sustained funding